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Frontiers of Medical Technology: Reflections on
the Intersection of Innovation and the Health Care
System
Susan Bartlett Foote*
In Professor Chen’s provocative introductory essay to this
issue, he notes that C.P. Snow’s observations in his famous
lecture, The Two Cultures, still resonate in our society.1 Snow
condemned the dominant literary culture’s failure to embrace
science and the consequences to the “underfed . . . [who] die
before their time.”2 Snow yearned for a bridge over the divide,
“something like a third culture,” comprising a community of
social scientists “concerned with how human beings are living
or have lived.”3
Recognizing the need for social science to build bridges,
University of Minnesota’s conference4 sought to address the
intersection between the “life sciences and the political
demands and social aspirations of the law.”5 My specific
challenge was to explore the interface between innovation in
medical technology and the political and social demands of the
health care delivery system. This interface is constantly
evolving in response to technological innovation.
C.P. Snow and his generation would be surprised by the
© 2005 Susan Bartlett Foote.
* J.D., M.A. Associate Professor, Division of Health Services Research
and Policy, University of Minnesota School of Public Health.
1. Jim Chen, The Midas Touch, 7 MINN. J.L. SCI. & TECH., at i (2005)
(citing C.P. SNOW, THE TWO CULTURES: AND A SECOND LOOK 22 (2d ed.
1964)).
2. SNOW, supra note 1, at 6-7.
3. Id. at 70.
4. “Where are Law, Ethics and the Life Sciences Headed? Frontier
Issues,” cosponsored by the University of Minnesota’s Consortium on Law and
Values in Health, Environment & the Life Sciences and Joint Degree Program
in Law, Health and the Life Sciences and the Minnesota Journal of Law,
Science & Technology (May 20, 2005).
5. Chen, supra note 1, at iii.
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rapid acceleration of advances in medical technology and its
enthusiastic embrace by Americans. From the perspective of
the 1950s, when Snow penned his controversial lecture,6 we
have taken an audacious leap. Medical technology harnesses
scientific and engineering advances, born out of the industrial
revolution and transformed in the late twentieth century, to
alter, replace, and repair a dizzying array of human functions.7
The success of technology in extending life and improving the
quality of life is reflected in the importance that Americans
place on access to health care. After all, we spent $1.7 trillion
or $5,670 per capita (15.3% of GDP), in 2003 on health.8
Indeed, just as science held the potential to ameliorate “the
underfed” of Snow’s day, so now does access to medical care, in
all of its technological splendor, distinguish between those who
have and those who have not.
It is essential to note that medical technology does not
enter American society unencumbered. Our embrace is not
unconditional; it is, in fact, quite fickle. Law conditions
medical technology’s arrival by imposing high social standards
of safety. Once a technology is approved for marketing, the
health care delivery system imposes further constraints.
Before embarking on an exploration of the intersection
between medical technology and law, we must clarify both
terms of the equation.
What do we mean by medical
technology? The Office of Technology Assessment once broadly
defined medical technology to include “drugs, devices, medical
surgical procedures used in medical care, and the
organizational and supportive systems within which such care
is provided.”9 It is not surprising that innovation across such a
wide range of activities varies significantly.
Examples of medical technology innovation abound. There
have been a plethora of new drugs introduced in the last few
decades, and the advent of biotechnology presents promise for
conventional pharmaceuticals and combinations of drugs and
6. See SNOW, supra note 1, at 1.
7. For a history of the evolution of medical technology, see generally
SUSAN BARTLETT FOOTE, MANAGING THE MEDICAL ARMS RACE: PUBLIC
POLICY AND MEDICAL DEVICE INNOVATION (1992).
8. See Cynthia Smith et al., Health Spending Growth Slows in 2003, 24
HEALTH AFF. 185-86 (2005).
9. OFFICE OF TECH. ASSESSMENT, MEDICAL TECHNOLOGY UNDER
PROPOSALS TO INCREASE COMPETITION IN HEALTH CARE, at ix (1982),
available
at
http://www.blackvault.com/documents/ota/Ota_4/DATA/1982/8218.PDF.
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biologics.10 Recent advances in molecular biology, proteomic
technologies, cellular and tissue engineering, and genomic
applications are just a few of the cutting-edge advances.11
Once an insignificant part of the medical arsenal, medical
devices are now used in thousands of interventions.12 Devices
include implanted artificial hips and knees, a wide range of
cardiac interventions, such as stents, pacemakers, and
defibrillators, medical lasers, and diagnostic tools, such as
magnetic resonance imaging, computerized tomography, and
There is significant
positron emission tomography.13
innovation on the horizon, including computer-assisted
telemanipulators that merge robotics, 3-D visualization
systems, and computer technology,14 and nanotechnology
applications,15 to name just a few. Medical device innovation
embraces the frontiers of science and engineering, adapting
computer technology, nanotechnology, and biotechnology to
Many of these technologies are
medical applications.16
delivered by physicians in in-patient and out-patient settings
and are embedded in the service delivery system.17 Physicians’
needs and experiences in clinical settings often trigger
innovation and incremental improvements; physicians also
require ongoing training to effectively use innovative
therapies.18
A few areas of medical technology, such as reproductive
techniques, cloning, and genetic manipulation, raise unique
controversial ethical issues. However, the focus here is on
10. See, e.g., John Miller, Beyond Biotechnology: FDA Regulation of
Nanomedicine, 4 COLUM. SCI. & TECH. L. REV. 1 (2003).
11. See generally Phil B. Fontanarosa & Catherine D. DeAngelis, Medical
Applications of Biotechnology, 293 J. AM. MED. ASS’N 866, 866-67 (2005).
12. See, e.g., HEALTH INDUS. MFRS. ASS’N, OUTLOOK FOR MEDICAL
TECHNOLOGY INNOVATION: WILL PATIENTS GET THE CARE THEY NEED?
REPORT 1: THE STATE OF THE INDUSTRY (2000).
13. See generally id. (discussing medical devices and the industry as a
whole).
14. See generally Mark A. Talamini & Eric J. Hanly, Technology in the
Operating Suite, 293 J. AM. MED. ASS’N 863, 863-66 (2005).
15. See Miller, supra note 10, at 5 (defining nanomedicine as “the
monitoring, repair, construction and control of human biological systems at
the molecular level, using engineered nanodevices and nanostructures”).
16. See HEALTH INDUS. MFRS. ASS’N, supra note 12, at 7-9.
17. See, e.g., id. at 12.
18. See, e.g., Cinda Becker, Shock Treatment, MODERN HEALTHCARE, May
9, 2005, at 34, 36 (discussing advances in electrophysiology and the concurrent
need for physician training).
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“workaday” medical products and procedures, many in
widespread use, that have become expected therapies for
patients and account for billions of dollars in health care
spending.19
Turning to the other term in the equation, references to
“law” in the context of health care are necessarily broadgauged. The American health care system is enormously
complex, with a mix of federal and state legislation and
regulation by a myriad of agencies.20 It is beyond the scope of
this paper to labor through a primer on the U.S. health care
system. What is important to note, however, is that medical
device technology can be directly and indirectly affected by a
wide range of laws and regulations and change in response to
innovation is a frequent occurrence.21
Each component of medical technology faces different
regulatory and legal hurdles. For example, the Food and Drug
Administration’s (FDA) authority has evolved to tailor
regulations to the specific characteristics of drugs, devices, and
biologics.22 The FDA does not have authority to directly
regulate physicians or the procedures that they perform; its
scope only extends to the products that physicians use.23 Often
change is triggered by a regulatory reaction to innovation.24
19. There are controversies surrounding how the costs of medical devices
specifically or medical technology generally are calculated to determine what
contribution they make to health care spending. One way is to look at the
costs of the devices themselves, scaled to market size. See HEALTH INDUS.
MFRS. ASS’N, supra note 12, at 13.
20. See FOOTE, supra note 7, at 26-52.
21. See id.
22. Indeed, the statutory definition of medical devices describes a series of
product types that are specifically “non-drugs,” meaning that they are not
metabolized by the human body:
The term “device” . . . means an instrument, apparatus, implement,
machine, contrivance, implant, in vitro reagent, or other similar or
related article, including any component, part, or accessory, which is
– (1) recognized in the official National Formulary, or the United
States Pharmacopeia, or any supplement to them, (2) intended for the
use in the diagnosis of disease or other conditions, or in the cure,
mitigation, treatment, or prevention of disease, in man or other
animals, or (3) intended to affect the structure or any function of the
body of man or other animals, and which does not achieve its primary
intended purposes through chemical action within or on the body of
man or other animals and which is not dependent upon being
metabolized for the achievement of its primary intended purposes.”
21 U.S.C. § 321(h) (2000) (emphasis added).
23. See FOOTE, supra note 7, at 44-45.
24. See Susan Bartlett Foote & Robert J. Berlin, Can Regulation Be as
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Change can also be triggered by product failures. Recent
product safety scandals involving antidepressants, painkillers,
and defibrillators have generated calls for FDA reforms.25
Payment, coverage, insurance, and liability issues also vary for
the components of medical technology.26 Because access to
drugs is considered an essential part of a complete health
regimen, increasingly there is a demand for insurance
coverage. The Medicare Prescription Drug, Improvement, and
Modernization Act of 200327 designed a drug benefit for
beneficiaries that will be implemented in 2006.28
The common theme is constant change. Technological
change has dramatically affected all aspects of health care, and
the health care system affects how that technology is
evaluated, accepted, diffused, and reimbursed.
If
“jurisdynamics” captures the concept of growth and change in
law,29 medical technology exemplifies growth and change in
health care.
At this intersection, then, between medical technology and
the health care system, are three “frontier policy issues”—
access to care, costs of care, and value of care. It is to these
that we now turn.
ACCESS TO CARE
The American approach to health care access is
ambivalent. Our government does not provide universal access
to care, unlike nations such as Japan or Canada where all
citizens are entitled to participate in the government-supported
health care system.30 Access to care in America is not so
Innovative as Science and Technology? The FDA’s Regulation of Combination
Products, 6 MINN. J.L. SCI. & TECH. 619, 619-39 (2005) (discussing this
phenomenon at length).
25. See Gardiner Harris, F.D.A. Responds to Criticism with New Caution,
N.Y. TIMES, Aug. 6, 2005, at A1.
26. See HEALTH INDUS. MFRS. ASS’N, supra note 12, at 52-62.
27. Medicare Prescription Drug, Improvement, and Modernization Act of
2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003).
28. For a discussion of the new prescription drug program, see Dana Gelb
Safran et al., Prescription Drug Coverage and Seniors: Findings from a 2003
National Survey, 24 HEALTH AFF. (WEB EXCLUSIVES) W5-152, W5-152 to W5166
(Supp.
1
2005),
available
at
http://content.healthaffairs.org/webexclusives/index.dtl?year=2005.
29. See generally Jim Chen, The Pragmatic Ecologist: Environmental
Protection as a Jurisdynamic Experience, 87 MINN. L. REV. 847 (2003).
30. See Strategic Pol’y & Research: Intergovernmental Affairs, Health
Care
Systems:
An
International
Comparison
4
(2001),
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simple.
Some Americans do receive health care as an
entitlement. For example, over forty million Americans qualify
for Medicare based on age, disability, and contribution to the
system.31 Others qualify for the Medicaid entitlement based on
state-based criteria of low income and other welfare-related
status indicators.32 Because the Medicaid entitlement is based
on status, changes due to income increases, for example, can
cause the loss of entitlement.33
Most other Americans must ensure access, if they can,
through private insurance.34 They purchase access either with
Because
employer assistance or on the open market.35
employers are not required to offer or subsidize insurance,
many working Americans do not have employment-based
coverage.36 Moreover, rising costs have led some employers to
drop insurance subsidies.37 The ranks of those without any
health insurance for at least some part of a year have swelled
during the past ten years.38 In 2003, the number of uninsured
Americans was forty-five million, and the uninsured population
is predicted to grow another twenty-five percent, to fifty-six
million Americans, by 2013.39
These individuals are not completely without access.
Medical technology and medical procedures are not perceived
as run-of-the-mill consumer goods, such as computers or
automobiles, which are available only to those with the
resources to purchase them. At some level, medical services
http://www.pnrec.org/2001papers/DaigneaultLajoie.pdf.
31. See http://www.medicare.gov (last visited Oct. 8, 2005).
32. See http://www.cms.hhs.gov (last visited Oct. 8, 2005).
33. See id.; see also http://www.ihs.gov (last visited Oct. 8, 2005)
(describing access to the Indian Health Service for certain Native Americans);
http://www.tricare.osd.mil (last visited Oct. 8, 2005) (describing access for
active duty service personnel, through the Department of Defense program
called Tricare); http://www.vba.va.gov (last visited Oct. 8, 2005) (describing
access for certain veterans through the Veterans Benefits Administration).
34. See GARY CLAXTON, KAISER FAMILY FOUND., HOW PRIVATE
INSURANCE WORKS: A PRIMER 1 (2002).
35. See id.
36. See KAISER FAMILY FOUND. & HEALTH RESEARCH & EDUC. TRUST,
EMPLOYER HEALTH BENEFITS: 2005 SUMMARY OF FINDINGS 4 (2005).
37. See id. at 11.
38. See Todd Gilmer & Richard Kronick, It’s the Premiums, Stupid:
Projections of the Uninsured Through 2013, 24 HEALTH AFF. (WEB
EXCLUSIVES) W5-143, W5-145 ex.1 (Supp. 1 2005), available at
http://content.healthaffairs.org/webexclusives/index.dtl?year=2005.
39. Id. at W5-148 to W5-149. For an extensive discussion of the
estimates, see generally id.
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are treated as “merit goods” that have greater social value and
should be more widely available.40 Therefore, hospitals are
required by law to treat any emergencies that arrive at their
doors, regardless of the insurance status of the patient.41
However, these patients lack access to nonemergency needs,
including elective, preventive, and life-saving technologies that
are not “emergencies.”
A recent New York Times article focused on access
differences based not on insurance status, but based on social
class.42 In the second in a series of articles titled Class Matters,
the reporter traced the effect of social class, defined as “that
elusive combination of income, education, occupation and
wealth,” on three patients who had heart attacks in New York
City.43 As Ichiro Kawachi, a professor of social epidemiology at
the Harvard School of Public Health, noted in the article: “It’s
like diffusion of innovation: whenever innovation comes along,
the well-to-do are much quicker at adopting it. . . . Mortality
rates even among the poor are coming down, but the rate is not
anywhere near as fast as for the well-to-do.”44 Bruce G. Link, a
professor at Columbia University, observed: “We’re creating
disparities. It’s almost as if it’s transforming health, which
used to be like fate, into a commodity. Like the distribution of
BMW’s or goat cheese.”45 Law and policy do not ensure
equitable access to health care, especially the high-tech care
associated with expensive drugs, devices, and life-enhancing
procedures.
Despite inequitable access to care, America spends more on
health care than any other nation.46 The rising costs of health
care threaten access for those who do not have sufficient
resources to pay. Technological change has played a role in
40. Merit goods are defined as “those goods and services to which people
are entitled as a birthright, simply by virtue of being members of society,
regardless of ability to pay.” Economic Brief No. 16: Merit Goods: A Policy
Dilemma, COMMUNITY LEADER’S LETTER (Clemson Univ. Cmty. & Econ. Dev.
Program, Clemson, S.C.), Summer 1994, at 2, available at
http://www.strom.clemson.edu/teams/ced/cll/5-2Summer94.pdf.
41. See 42 U.S.C. § 1395dd (2000).
42. See Janny Scott, Life at the Top in America Isn’t Just Better, It’s
Longer: Three Heart Attacks, and What Came Next, N.Y. TIMES, May 16, 2005,
at A1, A14-15.
43. Id. at A1.
44. Id. at A14.
45. Id.
46. See WORLD HEALTH ORG., THE WORLD HEALTH REPORT 2004:
CHANGING HISTORY 136–43 (2004).
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raising the cost of care. As the noted economists David Cutler
and Mark McClellan have found: “It is widely accepted that
technological change has accounted for the bulk of medical care
Thus, changing technology
cost increases over time.”47
exacerbates access problems.
COSTS OF CARE
Determining how technology in medicine affects costs is a
challenge. When a new technology substitutes for an older
version, the costs can either rise or fall. At the same time, new
technologies often lead to the expansion of the patient
population to be treated, resulting in higher overall costs. For
example, when cataract surgery was improved, the number of
surgical procedures grew.48 In 2003, the American College of
Cardiology reported that 70,785 heart patients were eligible for
expensive implantable cardiac defibrillators (ICDs).49 With
expanded coverage policies for patients not quite as sick as
traditional ICD patients, the estimate has grown to 240,000
eligible Medicare patients in 2005.50
Many reports praising the value of new medical
technologies are accompanied by lamentations about their
costs. At the end of an article on the future of surgical robotics,
the authors warn:
As surgery has rushed into the world of innovation, a few cautionary
flags are in order. Innovative technology is very expensive. Who is
going to pay for these advances? Which innovations are truly better
for patients and which are simply enticing? Who will pay for the
studies to distinguish between these? Are those technology-based
procedures that appear to be better truly cost-effective? Are there
sufficient safeguards in place? Should the free market be allowed to
decide which technologies will become entrenched, or should the
government take a bigger role?51

At the end of an article on ICDs, a consultant notes: “It’s
exciting, [but] it’s just that somebody has to pay for all of
this.”52
47. David M. Cutler & Mark McClellan, Is Technological Change in
Medicine Worth It?, 20 HEALTH AFF. 11, 11 (2001).
48. See IRVING SHAPIRO, MATTHEW D. SHAPIRO & DAVID W. WILCOX,
MEASURING THE VALUE OF CATARACT SURGERY 9 (1998), available at
http://www-personal.umich.edu/~shapiro/criw-rv2.pdf.
49. See Becker, supra note 18, at 34.
50. See id.
51. Talamini & Hanly, supra note 14, at 865-66.
52. Becker, supra note 18, at 36.
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VALUE OF CARE
Rising costs coupled with the rising number of uninsured
individuals have led to calls for change. A few have argued
that we need to ration access to costly technologies, similar to
efforts by Oregon to define limits for its Medicaid population.53
Many others have called for the rationalization of utilization of
technologies by subjecting innovations to greater scrutiny and
by seeking to eliminate services that do not produce net
improvements in health outcomes.
The Medicare program has undertaken significant changes
in its process for evaluating new technologies before making
coverage decisions.54 Research by John Wennberg and his
colleagues has shown significant variations in how medicine is
practiced across the country,55 concluding that hospital and
physician capacity is directly related to higher spending, often
The
without improved quality or length of life.56
Commonwealth Fund has also recently issued data
documenting variation in quality of care in the Medicare
Medicare is experimenting with pay-forprogram.57
performance demonstration projects,58 and physician groups
are working to impose practice standards on their members.59
53. See, e.g., Daniel M. Fox & Howard M. Leichter, Rationing Care in
Oregon: The New Accountability, 10 HEALTH AFF. 7 (1991) (discussing
Oregon’s rationing of its medical care resources).
54. For a discussion of the evolution of Medicare’s coverage process, see
Susan Bartlett Foote, Why Medicare Cannot Promulgate a National Coverage
Rule: A Case of Regula Mortis, 27 J. HEALTH POL. POL’Y & L. 707 (2002).
55. See John E. Wennberg, Practice Variations and Health Care Reform:
Connecting the Dots, 24 HEALTH AFF. (VARIATIONS REVISITED) VAR-140, VAR140 to VAR-144 (2004).
56. See John E. Wennberg, Elliot S. Fisher & Jonathan S. Skinner,
Geography and the Debate over Medicare Reform, 21 HEALTH AFF. (WEB
EXCLUSIVES)
W96,
W98
to
W102
(2002),
http://content.healthaffairs.org/webexclusives/index.dtl?year=2002.
57. See SHEILA LEATHERMAN & DOUGLAS MCCARTHY, COMMONWEALTH
FUND, QUALITY OF HEALTH CARE FOR MEDICARE BENEFICIARIES: A
CHARTBOOK
11
(2005),
available
at
http://www.cmwf.org/usr_doc/MedicareChartbk.pdf (concluding that despite
signs of progress, there is a wide variety of quality across the country).
58. Press Release, Center for Medicare & Medicaid Services, Medicare
“Pay
for
Performance
(P4P)”
Initiatives
(Jan.
31,
2005),
http://www.cms.hhs.gov/media/press/release.asp?Counter=1343.
59. See Warren A. Jones et al., Task Force Report 3: Report of the Task
Force on Continuous Personal, Professional, and Practice Development in
Family Medicine, 2 ANNALS FAM. MED. S65, S65-S74 (Supp. 2004); Doctor
Involvement Grows in Practice-Improvement Efforts, 59 MED. & HEALTH, Apr.
25, 2005, at 1-2.
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These efforts in the public and private sectors are aimed at
eliminating waste and reducing use of costly treatments whose
marginal value is low. That is an important goal. However, it
has been argued that these goals will “directly or indirectly
retard technological progress.”60 In addition, the fragmentation
of the American system makes comprehensive and effective
evaluation of new technology very difficult.
Americans have embraced the frontiers of medical
technology. They support investments in research and are avid
consumers of technology. Many of the fruits of that technology
have resulted in longer and better lives for many Americans.
These outcomes satisfy the call of C.P. Snow to harness science
and technology, to alleviate need, and to show concern for “how
human beings are living or have lived.”61 The challenge,
however, is formidable. Valuable medical technology must
navigate between the Scylla of rising costs and the Charybdis
of ensuring access to care.62 To date, our quest has been
elusive at best as we struggle to balance social and legal values
with science and technology in the service of improved health
for all Americans.

60. Cutler & McClellan, supra note 47, at 25.
61. SNOW, supra note 1, at 70.
62. See THOMAS BULFINCH, BULFINCH’S MYTHOLOGY: ILLUSTRATED
EDITION 243-45 (1979) (recounting the story of Scylla and Charybdis, who have
become “proverbial, to denote opposite dangers which beset one’s course”).

